Prelude Therapeutics Inc PRLD
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Prelude Therapeutics Inc (PRLD) is a healthcare company listed in the US with a market value of about $275M. In the twelve months to June 30, 2026 it had revenue of $22M and net income of -$60M, a net margin of -269.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -58%.
About Prelude Therapeutics
Prelude Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 62% over three years (dilution for shareholders). It spends 777% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | $12M | $7M | — | — | — | — | — |
| Net income | -$60M | -$99M | -$127M | -$122M | -$115M | -$112M | -$57M | -$28M |
| Free cash flow | -$33M | -$56M | -$104M | -$111M | -$87M | -$86M | -$47M | -$26M |
| EPS (diluted) | $-0.73 | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 | $-4.56 | $-16.52 |
| Net margin | -269.7% | -819.6% | -1816.8% | — | — | — | — | — |
| ROIC | — | -95.6% | -73.9% | -41.1% | -49.5% | -31.2% | -21.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $9.20, 167% above the current price; targets range from $6.00 to $12.00; the consensus rating is “none”; expected EPS is $-0.57 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Prelude Therapeutics pay a dividend?
Not currently.
Is Prelude Therapeutics a good stock to buy?
We do not give buy or sell advice. Prelude Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.